Pazopanib: an antiangiogenic drug in perspective

被引：16

作者：

Castaneda, Carlos A. ^{[1
]}

Gomez, Henry L. ^{[1
]}

机构：

[1] Inst Nacl Enfermedades Neoplas, Div Med, Lima, Peru

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 09期

关键词：

angiogenesis; breast; cervix; glyomas; lung; multiple myeloma; ovarian; pazopanib; renal; sarcomas; thyroid; tyrosine kinase; VEGF; ENDOTHELIAL-GROWTH-FACTOR; RENAL-CELL CARCINOMA; MULTIKINASE ANGIOGENESIS INHIBITOR; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; FACTOR VEGF OVEREXPRESSION; TYROSINE KINASE INHIBITOR; SOFT-TISSUE SARCOMA; PHASE-II; MULTIPLE-MYELOMA;

D O I：

10.2217/FON.09.112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway, It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

引用

页码：1335 / 1348

页数：14

共 84 条

[1]

Altorki N, 2008, ANN ONCOL, V19, P89

[2]

ALTORKI N, 2008, J CLIN ONCOL, V44, P7557

[3]

Bible KC, 2009, J CLIN ONCOL, V27

[4] HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors [J].

Blackwell, KL ;

Dewhirst, MW ;

Liotcheva, V ;

Snyder, S ;

Broadwater, G ;

Bentley, R ;

Lal, A ;

Riggins, G ;

Anderson, S ;

Vredenburgh, J ;

Proia, A ;

Harris, LN .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4083-4088

[5]

Brady J, 2009, J CLIN ONCOL, V27

[6] Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood [J].

Bremnes, RM ;

Camps, C ;

Sirera, R .

LUNG CANCER, 2006, 51 (02) :143-158

[7] Angiogenesis in ovarian cancer [J].

Brown, MR ;

Blanchette, JO ;

Kohn, EC .

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2000, 14 (06) :901-918

[8] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[9]

Casali PG, 2009, J CLIN ONCOL, V27

[10] Adverse effects of anticancer agents that target the VEGF pathway [J].

Chen, Helen X. ;

Cleck, Jessica N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) :465-477

← 1 2 3 4 5 6 7 8 9 →